{
    "ticker": "NBIS",
    "name": "NeuroBo Pharmaceuticals, Inc.",
    "description": "NeuroBo Pharmaceuticals, Inc. is a clinical-stage biotechnology company focused on developing innovative therapies for neurodegenerative diseases and other serious conditions. Founded in 2017, NeuroBo aims to address significant unmet medical needs through its proprietary drug candidates, which are designed to enhance the health and quality of life for patients suffering from diseases such as Alzheimer's and Parkinson's. The company's lead product candidate, NB-01, is being investigated for its potential to restore neuroplasticity and improve cognitive function in patients with neurodegenerative diseases. NeuroBo's research is rooted in scientific advancements in cellular biology and pharmacology, with a commitment to translating these discoveries into effective treatments. The company is dedicated to advancing its pipeline through rigorous clinical trials and collaborations with leading research institutions. NeuroBo's mission is to bring hope to patients and their families by developing therapies that can meaningfully improve outcomes in neurodegenerative diseases. By leveraging cutting-edge research and technology, NeuroBo is positioned to make a significant impact in the biotechnology sector.",
    "industry": [
        "Biotechnology",
        "Pharmaceuticals"
    ],
    "headquarters": "Boston, Massachusetts, USA",
    "founded": "2017",
    "website": "https://www.neurobopharma.com",
    "ceo": "Jeffrey D. Kauffman",
    "social_media": {
        "twitter": "https://twitter.com/neurobopharma",
        "linkedin": "https://www.linkedin.com/company/neurobo-pharmaceuticals/"
    },
    "investor_relations": "https://www.neurobopharma.com/investors",
    "key_executives": [
        {
            "name": "Jeffrey D. Kauffman",
            "position": "CEO"
        },
        {
            "name": "Michael D. Ainslie",
            "position": "CFO"
        }
    ],
    "product_categories": [
        {
            "category": "Therapeutics",
            "products": [
                "NB-01"
            ]
        }
    ],
    "seo": {
        "meta_title": "NeuroBo Pharmaceuticals, Inc. | Innovative Neurodegenerative Disease Therapies",
        "meta_description": "NeuroBo Pharmaceuticals is dedicated to developing innovative therapies for neurodegenerative diseases. Learn about our mission and pipeline.",
        "keywords": [
            "NeuroBo Pharmaceuticals",
            "Biotechnology",
            "Neurodegenerative Diseases",
            "NB-01",
            "Clinical Trials"
        ]
    },
    "faq": [
        {
            "question": "What does NeuroBo Pharmaceuticals focus on?",
            "answer": "NeuroBo Pharmaceuticals focuses on developing therapies for neurodegenerative diseases and serious health conditions."
        },
        {
            "question": "What is NeuroBo's lead product candidate?",
            "answer": "NeuroBo's lead product candidate is NB-01, aimed at improving cognitive function in neurodegenerative diseases."
        },
        {
            "question": "Where is NeuroBo headquartered?",
            "answer": "NeuroBo is headquartered in Boston, Massachusetts, USA."
        },
        {
            "question": "When was NeuroBo Pharmaceuticals founded?",
            "answer": "NeuroBo Pharmaceuticals was founded in 2017."
        }
    ],
    "competitors": [
        "AVXL",
        "SAVA",
        "PTLA"
    ],
    "related_stocks": [
        "AMGN",
        "GILD",
        "BIIB",
        "REGN"
    ]
}